🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Update on #COSMIC313 trial presented by the one and only Laurence Albiges: C+N+I showed sustained PFS & ORR benefits over P+N+I in 1L intermediate/poor risk pts. OS was similar between arms (HR 1.02). Addition of Cabo to N+I overcomes M2-like macrophage-mediated immune suppression

Updated clinical outcomes from the phase I study on cabozantinib (cabo) + nivolumab (nivo) with or without CBM588 in metastatic RCC patients! 📊🔬 New insights into combination therapy for better outcomes ASCO #GU25 Hedyeh Ebrahimi Sumanta K. Pal, MD, FASCO

Eye-opening talk by Turajlic Lab @ The Crick on the future of biomarkers in #RCC, especially genomic, highlighting important challenges ASCO #GU25 The Crick OncLive.com Yüksel Ürün Emre Yekedüz

New kid on the block! Toni Choueiri, MD HIF-2α Inhibitor Cas in ccRCC: Early Promise! -Active across IMDC risk groups in pretreated ccRCC. -Grade 3 anemia (36%) & hypoxia (6-9%), no Grade ≥4 TEAEs. -Next: PEAK-1 (Cas + Cabo) & first-line IO combo trials! #GU25 @asco @oncoalert

Amazing work from KCCure on disease burden among patients with mRCC. This matters as we design new treatments for patients with RCC. #GU25

Racial Disparities in RCC: Insights from France! Xiaofan Lu, PhD, UroCCR No race-based survival difference—unlike U.S. data, healthcare access may play a role. #GU25 @asco @oncoalert #cancer #oncology Toni Choueiri, MD Petros Grivas 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 OncLive.com Andrea Apolo, M.D. joaquim bellmunt

Excellent updated data from Cosmic 313. Positive PFS but no difference in OS. Many lessons learned. Transcriptomic work demonstrated tumors with high M2 macrophages derived benefit. Laurence Albiges Toni Choueiri, MD #GU25

Updated data from Calypso trial demonstrating activity of savolitinib + durvalumab in MET driven papillary RCC. #GU25 Toni Choueiri, MD Tom Powles

SAMETA: the 1st biomarker driven R3 papillary RCC study #GU25 . CALYPSO is the phase 2 data supporting it. RR PFS and OS in the MET driven group looks promising for durva/savolitinib. drfrankiejs also presents baseline and dynamic ctDNA analysis. A new biomarker in PRCC?

🔥 Excellent talk by Matt Campbell MD, MS diving into the mechanisms of immunotherapy resistance in RCC! 💡🔬 #RCC #GU25 #Immunotherapy

Great last session ASCO #GU25 - interactive case based discussions for hard to treat #kidneycancer. Good to see Raquibul Hannan representing UTSW Radiation Oncology UTSW Simmons Cancer Center on expert panel, along w friends Maite Bourlon Matt Campbell MD, MS Viraj Master!

Another nice slide by Maite Bourlon . Useful in clinics. Time off systemic therapy for major surgical intervention in advanced RCC . Note that Cabozantinib Needs to stop 3 weeks before surgery and Lenvatinib needs to stop one week before surgery. ASCO #GU25.

🆕Excited that our FKSI-23 measure, designed to assess HRQOL in patients with localized and advanced RCC, is available on the FACIT website: facit.org/measures/fksi-… Tom Powles Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Sarah P. Psutka MD MS Brian Rini, MD Elizabeth Plimack MD Viraj Master Viktor Grünwald Laurence Albiges

🎉Thrilled to support AACR Scholars-in-Training Dr. Xiaofan Lu & Dr. Emily Arner, with Chris Johnson Foundation Inc.. Thanks to all the fellow #kidneycancer supporting orgs and congrats to all the 2025 awardees! #aacr25 #cancerresearchsaveslives

We are excited to kick off #IKCSEU25 tomorrow! Tag us if you're on the way to Amsterdam! bit.ly/3OjTgfB

Brilliant work from Cristiane D Bergerot (mentored by Tom Powles) to introduce a novel #HRQOL metric for #kidneycancer. This one is different, folks! There are separate, short components of this that can be used for #localized & #metastatic dz (see “Scoring Document”). Developed with a

🚨#IKCS24 Proceedings is out! kidney-cancer-journal.com/IKCSNA-Proc.php 📕flipbook: kidney-cancer-journal.com/IKCS24-Proc2.p… 👉25 years of #ICKS24 - Special editorials by Brian Rini, MD Thomas Hutson, DO, PharmD, PhD FACP Salvatore La Rosa Kidney Cancer

So pleased to share research highlights from our #IKCSNA24 mtg marking ✨25 yrs✨ of the KCA's work to gather the scientific community! Find in-depth articles, editorials, and personal perspectives from leading #kidneycancer experts at Kɪᴅɴᴇʏ Cᴀɴᴄᴇʀ Jᴏᴜʀɴᴀʟ: kidney-cancer-journal.com/IKCSNA-Proc.php

Psst ... want to see how we're brewing up #ASCO25? We're busy behind the scenes making sure everything's just right! Can't WAIT to officially open the doors, welcome everyone, and get this Annual Meeting party started! See you there!

Welcome to #ASCO25! The energy is electric as we kick off a week of scientific discovery, breakthroughs, and inspiring connections. Get ready to dive deep into oncology advancements and shape the future of cancer care. We're thrilled you're here!